Drug updated on 11/15/2023
|Injection (subcutaneous; 284 mg/1.5 mL)
|Small interfering RNAs (siRNAs)
| Ongoing and
- Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).
Product Monograph / Prescribing Information
|Leqvio (inclisiran) Prescribing Information.
|Novartis Pharmaceuticals Corporation, East Hanover, NJ
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
|2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.
|Journal of the American College of Cardiology